000			02359 a2200745 4500
005			20250518090035.0
264		0	_c20210217
008			202102s 0 0 eng d
022			_a1528-0012
024	7		_a10.1053/j.gastro.2020.02.033 _2doi
040			_aNLM _beng _cNLM
100	1		_aZhao, Mingming
245	0	0	_aTMAVA, a Metabolite of Intestinal Microbes, Is Increased in Plasma From Patients With Liver Steatosis, Inhibits γ-Butyrobetaine Hydroxylase, and Exacerbates Fatty Liver in Mice. _h[electronic resource]
260			_bGastroenterology _c06 2020
300			_a2266-2281.e27 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAdolescent
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAnimals
650	0	4	_aBacteria _xmetabolism
650	0	4	_aBiomarkers _xblood
650	0	4	_aCase-Control Studies
650	0	4	_aCross-Sectional Studies
650	0	4	_aDiet, High-Fat
650	0	4	_aDysbiosis
650	0	4	_aFatty Acids, Nonesterified _xmetabolism
650	0	4	_aFeces _xmicrobiology
650	0	4	_aFemale
650	0	4	_aGastrointestinal Microbiome
650	0	4	_aHumans
650	0	4	_aIntestines _xmicrobiology
650	0	4	_aLipolysis _xdrug effects
650	0	4	_aLiver _xdrug effects
650	0	4	_aMale
650	0	4	_aMice, Inbred C57BL
650	0	4	_aMice, Knockout
650	0	4	_aMiddle Aged
650	0	4	_aNon-alcoholic Fatty Liver Disease _xchemically induced
650	0	4	_aOxidation-Reduction
650	0	4	_aUp-Regulation
650	0	4	_aValerates _xblood
650	0	4	_aYoung Adult
650	0	4	_agamma-Butyrobetaine Dioxygenase _xantagonists & inhibitors
700	1		_aZhao, Lin
700	1		_aXiong, Xuelian
700	1		_aHe, Yuan
700	1		_aHuang, Wei
700	1		_aLiu, Zihao
700	1		_aJi, Liang
700	1		_aPan, Bing
700	1		_aGuo, Xuefeng
700	1		_aWang, Leibo
700	1		_aCheng, Si
700	1		_aXu, Ming
700	1		_aYang, Hongyuan
700	1		_aYin, Yuxin
700	1		_aGarcia-Barrio, Minerva T
700	1		_aChen, Y Eugene
700	1		_aMeng, Xiangbao
700	1		_aZheng, Lemin
773	0		_tGastroenterology _gvol. 158 _gno. 8 _gp. 2266-2281.e27
856	4	0	_uhttps://doi.org/10.1053/j.gastro.2020.02.033 _zAvailable from publisher's website
999			_c30680249 _d30680249